2019
DOI: 10.20344/amp.9456
|Get access via publisher |Summarize |Cite
|
Sign up to set email alerts

Interstitial Lung Disease Induced by Crizotinib in Non-Small-Cell Lung Cancer

Abstract: The treatment of advanced non-small-cell lung cancer shifted with the development of molecular-targeted therapies, like the tyrosine kinase inhibitors. One example of tyrosine kinase inhibitors is crizotinib, an anaplastic lymphoma tyrosine kinase inhibitor, which targets an echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase gene fusion. This mutation is found in only 2% to 7% of non-small-cell lung cancer cases. Although these new therapies have shown promising results, the occurrence… Show more

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2
0
0

Citation Types

0
4
0
0

Year Published

Range
2019
2019
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations

Cited by 5 publications

(4 citation statements)
references

References 15 publications

0
4
0
0
Order By: Relevance
How this paper cites the one you are viewing
“…Chronic respiratory diseases are one of the leading causes of death globally. Victims of lung disorders frequently experience long-term difficulties, with one of the major causes being treatment side effects as well as psychosocial struggles [17]. Respiratory diseases are characterized by unrestricted cell proliferation and no single defined cause, but they are associated with several risk factors, including tobacco use, infection, radiation exposure, air pollution, obesity, and alcohol consumption.…”
Section: Introduction
mentioning
confidence: 99%